Inalways Asset Resilience Ratio
Inalways asset resilience ratio. Inalways (5398) has an Asset Resilience Ratio of 14.47% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Inalways fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Inalways (2015–2025)
Asset resilience ratio of Inalways from 2015 to 2025. This chart shows how Inalways's Asset Resilience Ratio has changed over time. Read 5398 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Inalways's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Inalways balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$82.59 Million | 14.47% |
| Total Liquid Assets | NT$82.59 Million | 14.47% |
Asset Resilience Insights
- Moderate Liquidity: Inalways has 14.47% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Inalways Industry Peers by Asset Resilience Ratio
Compare Inalways's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Inalways Asset Resilience Ratio by Year (2015–2025)
Inalways asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Inalways.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.33% | NT$56.03 Million ≈ $1.77 Million |
NT$600.79 Million ≈ $18.93 Million |
+0.04pp |
| 2024-12-31 | 9.29% | NT$60.65 Million ≈ $1.91 Million |
NT$653.17 Million ≈ $20.58 Million |
+5.17pp |
| 2023-12-31 | 4.12% | NT$22.92 Million ≈ $722.17K |
NT$556.64 Million ≈ $17.54 Million |
+0.37pp |
| 2022-12-31 | 3.75% | NT$22.84 Million ≈ $719.62K |
NT$608.73 Million ≈ $19.18 Million |
-4.68pp |
| 2021-12-31 | 8.43% | NT$54.60 Million ≈ $1.72 Million |
NT$647.84 Million ≈ $20.41 Million |
+1.98pp |
| 2020-12-31 | 6.44% | NT$41.71 Million ≈ $1.31 Million |
NT$647.31 Million ≈ $20.39 Million |
-2.37pp |
| 2019-12-31 | 8.82% | NT$58.96 Million ≈ $1.86 Million |
NT$668.56 Million ≈ $21.06 Million |
-3.87pp |
| 2018-12-31 | 12.69% | NT$79.91 Million ≈ $2.52 Million |
NT$629.72 Million ≈ $19.84 Million |
+7.12pp |
| 2017-12-31 | 5.57% | NT$43.31 Million ≈ $1.36 Million |
NT$777.58 Million ≈ $24.50 Million |
+1.74pp |
| 2016-12-31 | 3.83% | NT$29.43 Million ≈ $927.33K |
NT$769.13 Million ≈ $24.23 Million |
+3.11pp |
| 2015-12-31 | 0.71% | NT$2.45 Million ≈ $77.16K |
NT$343.08 Million ≈ $10.81 Million |
-- |
About Inalways
Mediera Corporation manufactures electronic and power supply components in Taiwan. It is also involved in the medical biotechnology business. The company offers medicines, health food, and medical device, etc. Mediera Corporation was founded in 1967 and is based in New Taipei City, Taiwan.